METROPOLISHEALTHCARE Healthcare 15 May 2026

Metropolis Healthcare Ltd — Q4 FY26

Metropolis Healthcare delivered a strong FY26 with group revenue of ₹1,646 crore (+23.6% YoY) and EBITDA margin of 24.4%.

bullish high

Revenue ₹1,646 Cr +23.6%

EBITDA ₹401 Cr +32%

PAT ₹191 Cr +31%

EBITDA Margin 24.4%

Duration 55 min

Read Time 1 min read

Financial stats pending filing verification

2-Minute Summary

✦ AI-Generated from Full Transcript

Metropolis Healthcare delivered a strong FY26 with group revenue of ₹1,646 crore (+23.6% YoY) and EBITDA margin of 24.4%. Organic revenue grew 13.7% YoY, exceeding the 12-13% guidance, driven by patient volume growth of 7.5% and realization improvement. Organic EBITDA margin expanded 140 bps to 25.9%, aided by lab platform upgrades, vendor consolidation, and operating leverage. The core diagnostics acquisition achieved high single-digit EBITDA margin within four quarters, on track for 20%+ in three years. Management guided for 14-15% organic revenue growth and 27-28% group EBITDA margin over the next three years, supported by network productivity gains, specialty mix improvement, and digital channel expansion. Key risks include competitive intensity in tier-1 cities and potential integration challenges from future M&A.

Key Numbers

Patient Volume Growth (Organic Q4) 9.3%

+9.3% YoY

Organic patient volume grew 9.3% in Q4 FY26, driven by network expansion and demand.

Realization Growth (Organic Q4) 5%

+5% YoY

Revenue per patient improved ~5% YoY in Q4, driven by specialty and wellness mix.

Digital Revenue Contribution 25%

+25pp vs 3 years ago

Digital channels now contribute 25% of revenue, up from 0% three years ago.

Center-to-Lab Ratio 24:1

+4pp YoY

Improved from 20:1 to 24:1, targeting 35:1 over three years.

Management Guidance

Organic revenue growth of 14-15% over next 3 years

Driven by 8-9% patient volume growth and ~5% realization improvement, with potential price increases.

Management guidance revenue

Group EBITDA margin target of 27-28% over next 3 years

Supported by operating leverage, productivity gains, and core diagnostics reaching 20%+ margin.

Management guidance margins

125-150 bps margin improvement in FY27

Management expects EBITDA margin expansion of 125-150 bps in the coming fiscal year.

Management guidance margins

Add 1500 collection centers and 100 mini hubs over 3 years

Expand asset-light network and upgrade centers to include basic radiology, targeting center-to-lab ratio of 35:1.

Management guidance expansion

Key Risks

Competitive intensity in tier-1 cities

Growth in tier-1 cities like Mumbai is around 11-14%, potentially constrained by high competition from organized and unorganized players.

medium · analyst_question

Integration risks from future M&A

While current acquisitions are on track, future deals may face quality and integration challenges, as management noted many assets do not meet their standards.

medium · management_commentary

Dependence on price increases for growth

Management indicated no price hike planned currently, but realization growth partly relies on future price increases, which may not materialize if competitive pressures persist.

low · data_observation

Notable Quotes

We are not looking at a price increase, but as the things progresses during the year, if there is a need for us to do it, we would not hesitate to do it.

Ameera Shah · Promoter Chairperson and Whole-time Director

We believe a sustainable EBITDA at this point over the next three years of 27 to 28% makes sense for us and if we are able to generate more operating leverage we would like to invest it back in the business.

Ameera Shah · Promoter Chairperson and Whole-time Director

Our lab addition phase is over... we are not planning to add a high number of labs in the network.

Surendran Cherukuri · Managing Director

Frequently Asked Questions

What was Metropolis Healthcare's revenue in Q4 FY26?

Metropolis Healthcare reported revenue of ₹1,646 Cr in Q4 FY26, representing a +23.6% change compared to the same quarter last year.

What guidance did Metropolis Healthcare management give for FY27?

Organic revenue growth of 14-15% over next 3 years: Driven by 8-9% patient volume growth and ~5% realization improvement, with potential price increases. Group EBITDA margin target of 27-28% over next 3 years: Supported by operating leverage, productivity gains, and core diagnostics reaching 20%+ margin. 125-150 bps margin improvement in FY27: Management expects EBITDA margin expansion of 125-150 bps in the coming fiscal year. Add 1500 collection centers and 100 mini hubs over 3 years: Expand asset-light network and upgrade centers to include basic radiology, targeting center-to-lab ratio of 35:1.

What are the key risks for Metropolis Healthcare in FY27?

Key risks include Competitive intensity in tier-1 cities — Growth in tier-1 cities like Mumbai is around 11-14%, potentially constrained by high competition from organized and unorganized players.; Integration risks from future M&A — While current acquisitions are on track, future deals may face quality and integration challenges, as management noted many assets do not meet their standards.; Dependence on price increases for growth — Management indicated no price hike planned currently, but realization growth partly relies on future price increases, which may not materialize if competitive pressures persist..

Did Metropolis Healthcare meet its previous quarter's guidance?

Scorecard data is being built as historical quarters are processed.

Where can I read the full Metropolis Healthcare Q4 FY26 concall transcript?

The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.